Somewhat Positive Press Coverage Somewhat Unlikely to Affect Aquinox Pharmaceuticals (AQXP) Share Price
News articles about Aquinox Pharmaceuticals (NASDAQ:AQXP) have been trending somewhat positive on Thursday, Accern reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Aquinox Pharmaceuticals earned a news impact score of 0.16 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.7687538675701 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Aquinox Pharma up 16% premarket on FDA advisory committee vote on IC/BPS studies – Seeking Alpha (seekingalpha.com)
- Aquinox Pharmaceuticals (AQXP) Given a $22.00 Price Target by Canaccord Genuity Analysts (americanbankingnews.com)
- Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) – GlobeNewswire (press release) (globenewswire.com)
- Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) (finance.yahoo.com)
Shares of Aquinox Pharmaceuticals (NASDAQ AQXP) traded up $0.20 on Thursday, reaching $10.47. The company’s stock had a trading volume of 110,400 shares, compared to its average volume of 85,981. Aquinox Pharmaceuticals has a 1 year low of $10.02 and a 1 year high of $19.97.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-aquinox-pharmaceuticals-aqxp-share-price/1763427.html.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.